PlateletBio
Mark is a managing partner of the Qiming U.S. Healthcare Fund. Previously, he served as chief operating officer of UCB Pharma, CEO of PDL BioPharma, CEO of Signature BioScience and COO of Boehringer Mannheim Therapeutics. He serves on the boards of FivePrime Therapeutics, Dermira Inc., and Aimmune Therapeutics. He received his M.B.A. from Harvard Business School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
PlateletBio
PlateletBio is the only allogeneic cell therapy company focused on platelet biology. The company's approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, they're developing a superior cell therapy empowered to tackle previously unmet medical challenges.